SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ImmunityBio converts from Immunomedics
IBRX 2.250-6.3%Nov 3 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Huggenberg6/15/2025 3:40:36 PM
2 Recommendations

Recommended By
bobbseytwins2001
erippetoe

   of 1222
 
Derivation of ImmunityBio's Car-NK strategy

After AI research, a potential strategy for ImmunityBio's future NK-92 and CAR-NK platform can be inferred from various clues provided by three AACR25 abstract posters.

Insights from the abstracts:

894: PD-L1 t-haNK in Phase 2 for GBM will be replaced with a memory-like variant (to avoid the danger of systemic IFN-gamma production).

885: The NK-92_B2MKO_HLAE cell line can be infused repeatedly into any patient without requiring HLA matching, offers a longer lifespan, and could be easily adapted into a CAR construct.

890: Both CAR constructs could be combined into a Stealth Memory-Activated t-haNK (SMAt-haNK) to provide the optimal solution for a high-performing CAR construct for solid tumors.

Conclusion:
Strategic Clinical Implications for ImmunityBio

1. First-mover in engineered NK-92-based immunotherapy
  • Most NK-based companies use donor or iPSC NK cells—NK-92 is highly engineerable and standardized, but usually short-lived. The ERIL-15 and stealth modifications solve that.
2. Best positioned for combo strategies
  • Platforms like ML PD-L1 t-haNK are ideal to pair with checkpoint inhibitors or ADCs (antibody-drug conjugates), maximizing synergistic killing.
3. Potential in relapsed/refractory solid tumors
  • Most NK trials are in hematologic malignancies; ImmunityBio is clearly pushing into solid tumor immunoresistance, a major unmet need.
4. Pipeline convergence: off-the-shelf CAR + stealth + memory
  • Their direction mimics the CAR-T field's evolution: from autologous > allogeneic > stealth > stem-like/memory > logic-gated.
  • t-haNK could become the "CAR-NK equivalent of T-cell 2.0" for broad oncology indications.
Details:

[url=https://cloud.hoststar.ch/s/FG546bHA6wgj9TA]IBRX Car-NK strategy[/url]
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News